{"entity":{"type":"insider","cik":"0001855980","url":"/insider/0001855980","json_url":"/insider/0001855980.json","name":"Secora Michael","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":39,"n_filings":17,"first":"2023-06-15","last":"2024-11-14","span_basis":"filed_date"},"name_variants":[{"name":"Secora Michael","source":"filing","n_filings":17,"first_seen":"2023-06-15","last_seen":"2024-11-14"}],"transactions":[{"id":3131279,"accession":"0001601830-24-000204","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000204","line_url":"/filing/0001601830-24-000204#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":7.6584,"price_display":"7.66","price_state":"stated","total_value":114876.0,"total_display":"114,876.00","total_whole":"114,876","shares_owned_after":1499631.0,"shares_owned_after_display":"1,499,631","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-13","filed_date":"2024-11-14","scope":"insider"},{"id":3131273,"accession":"0001601830-24-000204","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000204","line_url":"/filing/0001601830-24-000204#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":7.6419,"price_display":"7.64","price_state":"stated","total_value":114628.5,"total_display":"114,628.50","total_whole":"114,629","shares_owned_after":1475256.0,"shares_owned_after_display":"1,475,256","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-12","filed_date":"2024-11-14","scope":"insider"},{"id":2259001,"accession":"0001601830-24-000176","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000176","line_url":"/filing/0001601830-24-000176#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":6.3583,"price_display":"6.36","price_state":"stated","total_value":95374.5,"total_display":"95,374.50","total_whole":"95,375","shares_owned_after":1450881.0,"shares_owned_after_display":"1,450,881","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-09","filed_date":"2024-10-10","scope":"insider"},{"id":2258995,"accession":"0001601830-24-000176","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000176","line_url":"/filing/0001601830-24-000176#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":6.3171,"price_display":"6.32","price_state":"stated","total_value":94756.5,"total_display":"94,756.50","total_whole":"94,757","shares_owned_after":1426506.0,"shares_owned_after_display":"1,426,506","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-08","filed_date":"2024-10-10","scope":"insider"},{"id":2703165,"accession":"0001601830-24-000156","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000156","line_url":"/filing/0001601830-24-000156#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":6.3153,"price_display":"6.32","price_state":"stated","total_value":94729.5,"total_display":"94,729.50","total_whole":"94,730","shares_owned_after":1402131.0,"shares_owned_after_display":"1,402,131","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-11","filed_date":"2024-09-12","scope":"insider"},{"id":2703159,"accession":"0001601830-24-000156","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000156","line_url":"/filing/0001601830-24-000156#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":6.1666,"price_display":"6.17","price_state":"stated","total_value":92499.0,"total_display":"92,499.00","total_whole":"92,499","shares_owned_after":1377756.0,"shares_owned_after_display":"1,377,756","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-10","filed_date":"2024-09-12","scope":"insider"},{"id":3131262,"accession":"0001601830-24-000123","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000123","line_url":"/filing/0001601830-24-000123#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":6.3501,"price_display":"6.35","price_state":"stated","total_value":95251.5,"total_display":"95,251.50","total_whole":"95,252","shares_owned_after":1365343.0,"shares_owned_after_display":"1,365,343","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-14","filed_date":"2024-08-15","scope":"insider"},{"id":3131254,"accession":"0001601830-24-000123","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000123","line_url":"/filing/0001601830-24-000123#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":6.3455,"price_display":"6.35","price_state":"stated","total_value":95182.5,"total_display":"95,182.50","total_whole":"95,183","shares_owned_after":1340968.0,"shares_owned_after_display":"1,340,968","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-13","filed_date":"2024-08-15","scope":"insider"},{"id":2320167,"accession":"0001601830-24-000101","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000101","line_url":"/filing/0001601830-24-000101#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":7.2384,"price_display":"7.24","price_state":"stated","total_value":108576.0,"total_display":"108,576.00","total_whole":"108,576","shares_owned_after":1316593.0,"shares_owned_after_display":"1,316,593","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-10","filed_date":"2024-07-11","scope":"insider"},{"id":2320162,"accession":"0001601830-24-000101","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000101","line_url":"/filing/0001601830-24-000101#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":7.3185,"price_display":"7.32","price_state":"stated","total_value":109777.5,"total_display":"109,777.50","total_whole":"109,778","shares_owned_after":1292218.0,"shares_owned_after_display":"1,292,218","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-09","filed_date":"2024-07-11","scope":"insider"},{"id":2611159,"accession":"0001601830-24-000083","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000083","line_url":"/filing/0001601830-24-000083#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":9.2721,"price_display":"9.27","price_state":"stated","total_value":139081.5,"total_display":"139,081.50","total_whole":"139,082","shares_owned_after":1267843.0,"shares_owned_after_display":"1,267,843","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-14","filed_date":"2024-06-17","scope":"insider"},{"id":2611151,"accession":"0001601830-24-000083","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000083","line_url":"/filing/0001601830-24-000083#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":9.3199,"price_display":"9.32","price_state":"stated","total_value":139798.5,"total_display":"139,798.50","total_whole":"139,799","shares_owned_after":1243468.0,"shares_owned_after_display":"1,243,468","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-13","filed_date":"2024-06-17","scope":"insider"},{"id":2731762,"accession":"0001601830-24-000036","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000036","line_url":"/filing/0001601830-24-000036#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23124.0,"shares_display":"23,124","price_per_share":7.583,"price_display":"7.58","price_state":"stated","total_value":175349.292,"total_display":"175,349.29","total_whole":"175,349","shares_owned_after":1231055.0,"shares_owned_after_display":"1,231,055","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-17","filed_date":"2024-04-18","scope":"insider"},{"id":2731753,"accession":"0001601830-24-000036","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000036","line_url":"/filing/0001601830-24-000036#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":7.6663,"price_display":"7.67","price_state":"stated","total_value":191657.5,"total_display":"191,657.50","total_whole":"191,658","shares_owned_after":1216679.0,"shares_owned_after_display":"1,216,679","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-16","filed_date":"2024-04-18","scope":"insider"},{"id":2915470,"accession":"0001601830-24-000023","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000023","line_url":"/filing/0001601830-24-000023#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":11.0326,"price_display":"11.03","price_state":"stated","total_value":275815.0,"total_display":"275,815.00","total_whole":"275,815","shares_owned_after":1204179.0,"shares_owned_after_display":"1,204,179","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-13","filed_date":"2024-03-14","scope":"insider"},{"id":2915461,"accession":"0001601830-24-000023","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000023","line_url":"/filing/0001601830-24-000023#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":10.455,"price_display":"10.46","price_state":"stated","total_value":261375.0,"total_display":"261,375.00","total_whole":"261,375","shares_owned_after":1191679.0,"shares_owned_after_display":"1,191,679","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-12","filed_date":"2024-03-14","scope":"insider"},{"id":2060149,"accession":"0001209191-24-003410","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-24-003410","line_url":"/filing/0001209191-24-003410","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":10.456999608,"price_display":"10.46","price_state":"stated","total_value":261424.9902,"total_display":"261,424.99","total_whole":"261,425","shares_owned_after":1187418.0,"shares_owned_after_display":"1,187,418","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-14","filed_date":"2024-02-15","scope":"insider","n_lines":2},{"id":2060146,"accession":"0001209191-24-003410","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-003410","line_url":"/filing/0001209191-24-003410#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":9.8624,"price_display":"9.86","price_state":"stated","total_value":246560.0,"total_display":"246,560.00","total_whole":"246,560","shares_owned_after":1173851.0,"shares_owned_after_display":"1,173,851","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-13","filed_date":"2024-02-15","scope":"insider"},{"id":2516069,"accession":"0001209191-24-001868","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-24-001868","line_url":"/filing/0001209191-24-001868#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":10.2539,"price_display":"10.25","price_state":"stated","total_value":256347.5,"total_display":"256,347.50","total_whole":"256,348","shares_owned_after":981014.0,"shares_owned_after_display":"981,014","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-17","filed_date":"2024-01-18","scope":"insider"},{"id":2516067,"accession":"0001209191-24-001868","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-001868","line_url":"/filing/0001209191-24-001868#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":10.4464,"price_display":"10.45","price_state":"stated","total_value":261160.0,"total_display":"261,160.00","total_whole":"261,160","shares_owned_after":968514.0,"shares_owned_after_display":"968,514","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-16","filed_date":"2024-01-18","scope":"insider"},{"id":8609802,"accession":"0001209191-23-058703","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-23-058703","line_url":"/filing/0001209191-23-058703#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":7.5908,"price_display":"7.59","price_state":"stated","total_value":189770.0,"total_display":"189,770.00","total_whole":"189,770","shares_owned_after":956014.0,"shares_owned_after_display":"956,014","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-13","filed_date":"2023-12-14","scope":"insider"},{"id":8609795,"accession":"0001209191-23-058703","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-058703","line_url":"/filing/0001209191-23-058703#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":7.3947,"price_display":"7.39","price_state":"stated","total_value":184867.5,"total_display":"184,867.50","total_whole":"184,868","shares_owned_after":943514.0,"shares_owned_after_display":"943,514","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-12","filed_date":"2023-12-14","scope":"insider"},{"id":8658603,"accession":"0001209191-23-055610","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-23-055610","line_url":"/filing/0001209191-23-055610","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":7.3194456,"price_display":"7.32","price_state":"stated","total_value":182986.14,"total_display":"182,986.14","total_whole":"182,986","shares_owned_after":942886.0,"shares_owned_after_display":"942,886","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-15","filed_date":"2023-11-16","scope":"insider","n_lines":2},{"id":8658590,"accession":"0001209191-23-055610","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-055610","line_url":"/filing/0001209191-23-055610#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":6.3177,"price_display":"6.32","price_state":"stated","total_value":157942.5,"total_display":"157,942.50","total_whole":"157,943","shares_owned_after":925686.0,"shares_owned_after_display":"925,686","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-14","filed_date":"2023-11-16","scope":"insider"},{"id":8502021,"accession":"0001209191-23-052716","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-23-052716","line_url":"/filing/0001209191-23-052716#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":6.8525,"price_display":"6.85","price_state":"stated","total_value":171312.5,"total_display":"171,312.50","total_whole":"171,313","shares_owned_after":913186.0,"shares_owned_after_display":"913,186","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-11","filed_date":"2023-10-12","scope":"insider"},{"id":8502011,"accession":"0001209191-23-052716","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-052716","line_url":"/filing/0001209191-23-052716#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":7.0705,"price_display":"7.07","price_state":"stated","total_value":176762.5,"total_display":"176,762.50","total_whole":"176,763","shares_owned_after":900686.0,"shares_owned_after_display":"900,686","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-10","filed_date":"2023-10-12","scope":"insider"},{"id":8583393,"accession":"0001209191-23-049478","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-23-049478","line_url":"/filing/0001209191-23-049478#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":8.6927,"price_display":"8.69","price_state":"stated","total_value":217317.5,"total_display":"217,317.50","total_whole":"217,318","shares_owned_after":888186.0,"shares_owned_after_display":"888,186","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-13","filed_date":"2023-09-14","scope":"insider"},{"id":8583380,"accession":"0001209191-23-049478","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-049478","line_url":"/filing/0001209191-23-049478#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":8.4253,"price_display":"8.43","price_state":"stated","total_value":210632.5,"total_display":"210,632.50","total_whole":"210,633","shares_owned_after":875686.0,"shares_owned_after_display":"875,686","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-12","filed_date":"2023-09-14","scope":"insider"},{"id":8043870,"accession":"0001209191-23-046423","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-23-046423","line_url":"/filing/0001209191-23-046423#line-5","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":8.9007,"price_display":"8.90","price_state":"stated","total_value":222517.5,"total_display":"222,517.50","total_whole":"222,518","shares_owned_after":863186.0,"shares_owned_after_display":"863,186","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-16","filed_date":"2023-08-17","scope":"insider"},{"id":8043863,"accession":"0001209191-23-046423","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-046423","line_url":"/filing/0001209191-23-046423#line-3","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":9.2717,"price_display":"9.27","price_state":"stated","total_value":231792.5,"total_display":"231,792.50","total_whole":"231,793","shares_owned_after":850686.0,"shares_owned_after_display":"850,686","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-15","filed_date":"2023-08-17","scope":"insider"},{"id":8221581,"accession":"0001209191-23-042798","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-23-042798","line_url":"/filing/0001209191-23-042798","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":15.533930704,"price_display":"15.53","price_state":"stated","total_value":388348.2676,"total_display":"388,348.27","total_whole":"388,348","shares_owned_after":852772.0,"shares_owned_after_display":"852,772","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-07-19","filed_date":"2023-07-19","scope":"insider","n_lines":3},{"id":8221561,"accession":"0001209191-23-042798","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-042798","line_url":"/filing/0001209191-23-042798","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":13.632088,"price_display":"13.63","price_state":"stated","total_value":340802.2,"total_display":"340,802.20","total_whole":"340,802","shares_owned_after":830913.0,"shares_owned_after_display":"830,913","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-07-18","filed_date":"2023-07-19","scope":"insider","n_lines":2},{"id":8154414,"accession":"0001209191-23-037582","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-23-037582","line_url":"/filing/0001209191-23-037582#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":10.0735,"price_display":"10.07","price_state":"stated","total_value":251837.5,"total_display":"251,837.50","total_whole":"251,838","shares_owned_after":817913.0,"shares_owned_after_display":"817,913","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-14","filed_date":"2023-06-15","scope":"insider"},{"id":8154408,"accession":"0001209191-23-037582","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-037582","line_url":"/filing/0001209191-23-037582#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001855980","owner_name":"Secora Michael","owner_display_name":"Secora Michael","owner_url":"/insider/0001855980","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":9.9323,"price_display":"9.93","price_state":"stated","total_value":248307.5,"total_display":"248,307.50","total_whole":"248,308","shares_owned_after":805413.0,"shares_owned_after_display":"805,413","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-13","filed_date":"2023-06-15","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":39,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":39,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":39},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001601830","name":"RECURSION PHARMACEUTICALS, INC.","url":"/issuer/0001601830","role":"Officer (Chief Financial Officer)","n_filings":17,"first_seen":"2023-06-15","last_seen":"2024-11-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001855980","retrieved_at":"2026-08-27T09:33:53+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}